Normal Tension Glaucoma
Conditions
Brief summary
A randomized, multicenter, investigator-masked prospective study of NTG patients currently on latanoprost 0.005% monotherapy, to study the effect of IOP change with the introduction of netarsudil 0.02% vs brimonidine 0.1%. Subjects will be assessed at a screening visit, and 1 follow-up visit. Clinical evaluations will include visual acuity and IOP .
Interventions
DRUGNetarsudil
netarsudil 0.02%
DRUGBrimonidine
brimonidine 0.1%
Sponsors
Sengi
Westlake Eye Specialists
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients 18 years and older * Diagnosed with normal tension glaucoma based on the following: * IOP ≤ 21mmHg * Optic nerve rim thinning and/or retinal nerve fiber layer (RNFL) loss consistent with glaucoma * Normal visual field OR visual field loss consistent with optic nerve or RNFL defects within the last year * Open angles assessed by gonioscopy * Have been on latanoprost monotherapy for at least 6 weeks
Exclusion criteria
If any of the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean diurnal intraocular pressure | After 6 weeks of treatment | Intraocular pressure will be measure at 8am, 12pm, and 4pm |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of diurnal intraocular pressure reduction | After 6 weeks of treatment | Intraocular pressure will be measure at 8am, 12pm, and 4pm |
| Mean intraocular pressure at 8am | After 6 weeks of treatment | — |
| Mean intraocular pressure at 12pm | After 6 weeks of treatment | — |
| Mean intraocular pressure at 4pm | After 6 weeks of treatment | — |
Countries
United States
Outcome results
None listed